To provide a partial solution to the data issues and improve early drug safety assessment, an effort has been made to integrate preclinical and post-marketing drug safety data with other commonly used sources of information, such as chemical structure data and preclinical assays. Current trends focus on developing novel systems approaches to drug safety that offer a more mechanistic view of predictive safety based on similarity to drug classes, interaction with secondary targets, and interference with biological pathways beyond the traditional identification of chemical fragments associated with selected toxicity criteria . An example of the integration of this information is CLARITYPV , a web platform for translational safety and pharmacovigilance studies that track side effects throughout all phases of the drug discovery and development process.